Biohaven (NYSE:BHVN) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for neurological and neuropsychiatric diseases. The company’s primary expertise lies in peptide-based small molecules designed to target calcitonin gene-related peptide (CGRP) pathways, N-methyl-D-aspartate (NMDA) receptor modulation and other novel mechanisms of action. Biohaven’s scientific platform combines rational drug design with translational neuroscience to address unmet needs in migraine, neuropathic pain, neuroinflammation and rare neurological disorders.
Among Biohaven’s flagship products is rimegepant, marketed under the brand name Nurtec® ODT, an orally disintegrating tablet approved for the acute and preventive treatment of migraine. The company also advanced zavegepant, an intranasal CGRP receptor antagonist, and continues to expand its pipeline with candidates targeting NMDA receptor subtypes for conditions such as treatment-resistant depression and movement disorders. In addition to its proprietary assets, Biohaven has entered strategic collaborations and out-licensed certain programs to streamline its development efforts and maximize global reach.
Founded in 2013 and headquartered in New Haven, Connecticut, Biohaven has established operations in North America and partnerships to extend its investigational therapies into Europe and Asia. The company’s research capabilities are supported by state-of-the-art laboratories and alliances with academic institutions specializing in neuroscience. In October 2022, Biohaven was acquired by Pfizer, enhancing its resources and providing broader commercial infrastructure for Neurology and Rare Disease franchises.
Under the leadership of Founder and Chief Executive Officer Dr. Vladimir “Vlad” Coric, Biohaven assembled a management team with deep expertise in drug discovery, clinical development and commercialization. Dr. Coric, who previously contributed to major neuroscience programs at leading pharmaceutical firms, continues to guide Biohaven’s strategic vision in advancing innovative therapies for patients with serious brain disorders.
